Medicare gets sharper teeth to negotiate drug prices—50 drugs, 3-year patent lock, steeper discounts

What it does

This bill accelerates and strengthens Medicare's drug price negotiation program by increasing the number of drugs subject to negotiation from 15 to 50 per year starting in 2028, shortening the patent exclusivity period that blocks negotiation from 7–11 years to 3 years across the board, and lowering the price ceiling Medicare can negotiate to (reducing the maximum allowable price from 75–40% of average manufacturer price to 76–30%). The result: Medicare gains more negotiating power over more drugs sooner, potentially lowering drug costs for seniors and reducing federal spending on pharmaceuticals.

Why we flagged it

The bill's sole operative purpose is to strengthen Medicare's existing drug price negotiation authority by accelerating timelines, broadening eligible drugs, and lowering negotiated price ceilings. It is a direct policy amendment to the Inflation Reduction Act's drug pricing framework.

What the text implies

• Shortening patent exclusivity from 7–11 years to 3 years may accelerate generic/biosimilar entry and reduce the effective market exclusivity period for new drugs, potentially affecting R&D incentives and drug development timelines.
• Lowering the price ceiling to 30% of average manufacturer price (from 40%) in year 3+ of negotiation may force manufacturers to accept steeper discounts or withdraw drugs from Medicare, creating potential access or supply-chain risks if manufacturers choose not to participate.

The full analysis lists 4 implications of this text.

Who stands to gain

Medicare beneficiaries (seniors, disabled individuals); U.S. federal government (reduced Medicare spending); State Medicaid programs (potential spillover savings if state drug pricing aligns)